uniQure N.V. Payment for Contingent Consideration Liability, Financing Activities
uniQure N.V. (QURE) reported Payment for Contingent Consideration Liability, Financing Activities of $8.56 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities · last filed 2026-03-02
- uniQure N.V. payment for contingent consideration liability, financing activities for the quarter ending 2023-12-31 was $0.00.
- uniQure N.V. payment for contingent consideration liability, financing activities for fiscal 2024 was $8.56M, a 11.90% increase from fiscal 2023.
- uniQure N.V. payment for contingent consideration liability, financing activities for fiscal 2023 was $7.65M.
- uniQure N.V. payment for contingent consideration liability, financing activities for fiscal 2017 was $582.00K.
| Period end | Payment for Contingent Consideration Liability, Financing Activities 3 month | Payment for Contingent Consideration Liability, Financing Activities 9 month | Payment for Contingent Consideration Liability, Financing Activities 12 month |
|---|---|---|---|
| 2024-12-31 | $8.56M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $7.65M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $7.65M 10-Q · filed 2024-11-05 | ||
| 2017-12-31 | $582.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |